HCV viraemia is more important than genotype as a predictor of response to interferon in Sicily (Southern Italy)

Journal of Hepatology

Volumn 25, Issue 5, 1996, Pages 583-590

  Magrin, Silvio ^a   Craxi, Antonio ^d   Fabiano, Carmelo ^a   Marino, Liliana ^a   Fiorentine, Germana ^a   Lo Iacono, Oreste ^d   Volpes, Riccardo ^d   Di Marco, Vito ^d   Almasio, Piero ^d   Vaccaro, Alessandra ^d   Urdea, Mickey S ^b   Wilber, Judith C ^b   Bonura, Celestino ^d   Gianguzza, Fabrizio ^d   Capursi, Vincenza ^d   Filiberti, Salvatore ^d   Stuyver, Lieven ^c   Pagliaro, Luigi ^d  

^a VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

^c INNOGENETICS   (Belgium)

^d NONE

Author keywords

Genotype; HCV RNA; Hepatitis C; Hepatitis C virus; Interferon; Prediction; Viremia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON;

ADULT; ARTICLE; CHRONIC LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ITALY; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS INFECTION;

EID: 0030297385     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80224-8     Document Type: Article

References (55)

1. 1. Tinè F, Magrin S, Craxi A, Pagliaro L. Interferon in nonA nonB hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991; 13: 192-9.
2. 2. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol 1994; 21: 12-7.
3. 3. Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono O, Almasio P. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-8.
4. 4. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-9.
5. 5. Kobayashi Y, Watanabe S, Konishi M, Yokoi M, Kakehashi R, Kaito M, Kondo M, Hayashi Y, Jomori T, Suzuki S. Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon beta. Hepatology 1993; 18: 1319-25.
6. 6. Aiyama T, Yoshioka K, Hirofuji H, Kusakabe A, Yamada M, Tanaka K, Kakumu S. Changes in serum hepatitis C virus RNA titer and response to interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 2244-9.
7. 7. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobayashi M, Hiromitsu K. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088-94.
8. 8. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H, Kamada T. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977-82.
9. 9. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to efficacy of interferon-alpha2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994; 39: 1273-80.
10. 10. Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Kashiwagi S. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-6.
11. 11. Yun ZB, Reichard O, Chen M, Lundeberg J, Norkrans G, Fryden A, Sonnerborg A, Weiland O. Serum hepatitis C virus RNA levels in chronic hepatitis C. Importance for outcome of interferon-alpha2b treatment. Scand J Infect Dis 1994; 26: 263-70.
12. 12. Lau JYN, Davis GL, Kniffen J, Qian K-P, Urdea MS, Chan CS, Mizokami M, Neuwald PD, Wilber JC. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
13. 13. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Lo Iacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Pescador R, Detmer J, Wilber JC, Pagliaro L. Hepatitis C viraemia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 1994; 19: 273-9.
14. 14. Orito E, Mizokami M, Nakano T, Terashima H, Nojiri O, Sakakibara K, Mizuno M, Ogino M, Nakamura M, Matsumoto Y, Miyata K-I, Lau JYN. Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. J Med Virol 1994; 44: 410-4.
15. 15. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH, Sallie R. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994; 20: 1405-11.
16. 16. Rumi MG, Romeo R, Parravicini ML, Soffredini R, Pacchetti S, Donato MF, Ronchi G, Del Ninno E, Wilber J, Colombo M. Randomized comparative study of recombinant alpha and lymphoblastoid interferon in patients with chronic active hepatitis C. J Hepatol 1994; 21: S27.
17. 17. Ravaggi A, Puoti M, Rossini A, Marin MG, Bresciani S, Albertini A, Cariani E. HCV genotype and viraemia: predictive value for early and sustained response to interferon therapy. J Hepatol 1994; 21: S64.
18. 18. Portal I, Bourliere M, Hafon PH, Gerolami V, Khiri H, Cartouzou G, Garnier PP, Castellani P, Antoni M, Botta-Fridlund D, Gauthier AP. Predictive value of serum HCV-RNA levels and genotypes for response to interferon alpha therapy. Hepatology 1994; 20: 156A.
19. 19. Mizokami M, Orito E, Susuki K, Ohba K, Ohno T, Mizoguchi N, Koide T, Terashima H, Nekano T, Urdea MS, Lau JYN. Predictors of long-term response to interferon-alpha therapy in Japanese patients with chronic hepatitis C. Hepatology 1994; 20: 158A.
20. 20. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122: 161-8.
21. 21. Yamada G, Takatani M, Fishi F, Takahashi M, Doi T, Tsuji T, Shin S, Tanno M, Urdea MS, Kolberg JA. Efficacy of interferon alfa therapy in chronic hepatitis C depends primarily on hepatitis C virus RNA level. Hepatology 1995, 22: 1351-4.
22. 22. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum HCV-RNA levels and HCV genotype are the main independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 1995; 22: 1050-6.
23. 23. Dusheiko G, Schmilovitz-Weiss H, Brown D, McOmish F, Yap P-L, Sherlock S, McIntyre N, Simmonds P. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994; 19: 13-8.
24. 24. Pol S, Thiers V, Nousbaum J-B, Legendre C, Berthelot P, Kreis H, Brechot C. The changing prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995; 108: 581-3.
25. 25. Pawlotsky J-M, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J, Dhumeaux D. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995; 171: 1607-10.
26. 26. Pontisso P, Ruvoletto MG, Nicoletti M, Tisminetzky S, Gerotto M, Levrero M, Artini M, Baldi M, Ballardini G, Barbara L, Bonetti P, Brillanti S, Casarin C, Chemello L, Costanzo A, De Mitri MS, Donada C, Felaco MF, Frezza M, Gaeta GB, Giostra F, Iervese T, Lo Iacono O, Milella M, Monno L, Negro F, Piccinino F, Russo G, Vaccaro A, Baralle F, Alberti A. Distribution of three major hepatitis C virus genotypes in Italy. A multicentre study of 495 patients with chronic hepatitis C. J Viral Hepatitis 1995; 2: 33-8.
27. 27. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW. Formulation and application of a numerical scoring system for assessing histologic activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
28. 28. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
29. 29. Desmet VJ, Gerger M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
30. 30. Urdea MS, Horn T, Fultz TJ, Anderson M, Running JA, Hamren S, Ahle D, Chang C. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl Acids Res 1991; 24: 197-200.
31. 31. Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, Tsuda F, Miyakawa Y, Mayumi M. The 5′-terminal sequence of hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167-77.
32. 32. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339: 237-8. (Erratum, Nature 339: 490, 1989).
33. 33. Lau JYN, Simmonds P, Urdea MS. Implications of variations of "conserved" regions of hepatitis C virus genome. Lancet 1995; 346: 425-6.
34. 34. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102.
35. 35. Casanova JL, Pannetier C, Jaulin C, Kourilsky P. Optimal conditions for directly sequencing double-stranded PCR products with Sequenase. Nucl Acids Res 1990; 18: 4028.
36. 36. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
37. 37. Tabor S, Richardson CC. DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc Natl Acad Sci USA 1987; 4767-71.
38. 38. Newton CR, Kalsheker N, Graham A, Powell S, Gammack A, Riley J, Markham AF. Diagnosis of alpha-1-antitrypsin deficiency by enzymatic amplification of human genomic DNA and direct sequencing of polymerase chain reaction products. Nucl Acids Res 1988; 16: 8234-42.
39. 39. SAS Institute, Inc., SAS/STAT User's Guide, Version G, Fourth Edition, Vol 1, 1990. Cary, North Carolina, USA.
40. 40. Van Doorn L-J. Review: molecular biology of the hepatitis C virus. J Med Virol 1994; 43: 345-56.
41. 41. Smith DB, Mellor J, Jarvis LM, Davidson F, Kolberg J, Urdea M, Yap P-L, Simmonds P. Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing. J Gen Virol 1995; 76: 1749-61.
42. 42. Wasson JH, Sox HC, Neff RK, Goldman L. Clinical prediction rules. Applications and methodological standards. N Engl J Med 1985; 313: 793-9.
43. 43. Harrel FE, Lee KL, Matchar DB, Reichert TA. Regression Models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985; 69: 1071-7.
44. 44. Chemello L, Alberti A, Rose K, Simmonds P. Hepatitis C serotype and response to interferon therapy. N Engl J Med 1994; 330: 143.
45. 45. Dusheiko G, Alberti A, Colombo M, Craxi A, Frost C, Prieto J, Sanchez-Tapias J. The influence of serotypes of hepatitis C virus on sustained response to alpha interferon treatment. J Hepatol 1994; 21: S17.
46. 46. Van Doorn L-J, Kleter B, Stuyver L, Maertens G, Brouwer H, Schalm S, Heijtink R, Quint W. Analysis of hepatitis C virus genotypes by a line probe assay and correlation with antibody profiles. J Hepatol 1994; 21: 122-9.
47. 47. Lau JYN, Mizokami M, Kolberg JA, Davis JL, Prescott LE, Ohno T, Perillo RP, Lindsay KL, Gish RG, Qian K-P, Kohara M, Simmonds P, Urdea MS. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995; 171: 281-9.
48. 48. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kishida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995; 21: 291-7.
49. 49. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnu L, Casarin C, Alberti A, and the TriVeneto Viral Hepatitis Group. Randomized trial comparing different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
50. 50. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121-30.
51. 51. Moribe T, Hayashi N, Kanazawa Y, Mita E, Fusamoto H, Negi M, Kaneshige T, Igimi H, Kamada T, Uchida K. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. Gastroenterology 1995; 108: 789-95.
52. 52. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66: 3225-9.
53. 53. Tsukiyama-Kohara K, IIzuka N, Kohara M, Nomoto A. Internal ribosome entry site within hepatitis C virus RNA. J Virol 1992; 66: 1476-83.
54. 54. Pozzato G, Kaneko S, Moretti M, Croce LS, Franzin F, Unoura M, Bercich L, Tiribelli C, Crovatto M, Santini G, Kobayashi K. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291-6.
55. 55. Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, Takayanagi M. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994; 39: 234-9.